Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 1
1(20.0%)
5Total
Phase 2(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03322865Phase 2Active Not Recruiting

Obinutuzumab in Marginal Zone Lymphoma

Role: collaborator

NCT03474744Phase 2Active Not Recruiting

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

Role: collaborator

NCT04268277Phase 2Terminated

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Role: collaborator

NCT06272084Recruiting

Analysis of TPE Treatments With multiFiltratePRO

Role: collaborator

NCT03592342Phase 2Completed

Intra-oral Treatment of OLP With Rivelin®-CLO Patches

Role: collaborator

NCT01621256Phase 1Completed

Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss

Role: collaborator

All 6 trials loaded